$CLDI | Calidi Q3 2024 Financial Results:

🔹 Net loss: $5.1 million, or $0.65 per share, compared to a net loss of $2.0 million, or $1.41 per share, for the same period in 2023 🟢

🔹 Research and development expenses: $2.2 million, compared to $3.3 million for the comparable period in 2023 🟢

🔹 General and administrative expenses: $3.1 million, compared to $4.0 million for the comparable period in 2023 🟢

🔹 The Company had approximately $1.9 million in cash and $0.2 million in restricted cash as of both September 30, 2024 and December 31, 2023 🟢

Recent Corporate Developments

🔸 Announced FDA Clearance of the Northwestern University IND Application for NeuroNova (CLD-101) Clinical Trial in High-Grade Glioma

🔸Presented data supporting RTNova (CLD-400), the company’s systemic antitumor virotherapy platform, at the International Oncolytic Virotherapy Conference (IOVC) in Rotterdam, Netherlands, the Society for Immunotherapy of Cancer (SITC) Annual Meeting, and at Immuno US 2024 in San Diego, California

🔸 Raised $2 million in a registered direct offering and concurrent private placement

I think I am going to increase my positions... 👀👀👀

NOT FINANCIAL ADVICE!